From Digital Biomanufacturing to mAb Production, Keynoters to Share Insights During August 12-16, 2019 Conference in Boston
Boston, MA, June 12, 2019—To meet exploding demand for biological drugs that can cure fatal diseases, counter chemical threats, or fight cancer, the bioprocessing industry is evolving to “digital biomanufacturing”— capitalizing on innovations like predictive analytics to fast track their protein-based therapies.
From August 12-16, 2019, more than 1,500 scientists, engineers and leaders from this international community will unite at The Bioprocessing Summit in Boston to explore the transformation ahead. They will also share new solutions to the challenges they encounter today, as they work to maximize quality, safety and cost-efficiency in the biologics manufacturing process.
“Distinguished by its high-caliber scientific content, the eleventh annual Bioprocessing Summit will offer abundant opportunities to access new data, case studies, technologies and techniques, and initiate valuable collaborations,” said Mary Ruberry, Senior Conference Director, Cambridge Healthtech Institute, which produces this event.
This year’s Plenary Keynote Sessions will focus on current challenges and future innovations:
Leading to Tomorrow’s Advances (August 12)
Biologic Therapies in the Coming Decade: Modalities and Development Strategies, with Yatin Gokarn, PhD, Vice President, Global Head, Biologics Drug Product Development, Sanofi Pharmaceuticals
The Future of Bioprocessing – A Digital Era Awaits, with Anthony Mire-Sluis, PhD, Head, Global Quality, AstraZeneca Pharmaceuticals
Session Chairperson Sue Behrens, PhD, Senior Director, Process Design, IPS, will kick off the program
Solving Today’s Challenges (August 14)
Evolving Trends in mAb Production Processes, with Sanchayita Ghose, PhD, Director, Biologics Process Development, Bristol-Myers Squibb Co.
Today’s Challenges and Opportunities in Biomanufacturing, with Judy Chou, PhD, Senior Vice President and Global Head, Biotech, Bayer Pharmaceuticals
Session Chairperson John Sterling, Editor, Genetic Engineering & Biotechnology News, will open the discussions
The Bioprocessing Summit will include 200+ presentations on upstream and downstream processing, analytical and quality, formulation and stability, cell and gene therapy, manufacturing, and more.
In addition to one-on-one networking, an Exhibit Hall with 110+ cutting-edge innovators, and 80+ poster sessions, the conference will feature training seminars, special events sponsored by the International Society for Cell and Gene Therapy (ISCT), Women in Bio (WIB) and The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), breakout discussions and short courses.
Please see bioprocessingsummit.com.
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.
Contact Dawn Ringel
781-449-8456 or [email protected]